JP2022541550A5 - - Google Patents

Info

Publication number
JP2022541550A5
JP2022541550A5 JP2022503463A JP2022503463A JP2022541550A5 JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5 JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5
Authority
JP
Japan
Prior art keywords
level
upper limit
less
pharmaceutical composition
reference range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042820 external-priority patent/WO2021016208A1/en
Publication of JP2022541550A publication Critical patent/JP2022541550A/ja
Publication of JP2022541550A5 publication Critical patent/JP2022541550A5/ja
Pending legal-status Critical Current

Links

JP2022503463A 2019-07-19 2020-07-20 先天性副腎過形成を処置する方法 Pending JP2022541550A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876176P 2019-07-19 2019-07-19
US62/876,176 2019-07-19
US202063047822P 2020-07-02 2020-07-02
US63/047,822 2020-07-02
PCT/US2020/042820 WO2021016208A1 (en) 2019-07-19 2020-07-20 Methods of treating congenital adrenal hyperplasia

Publications (2)

Publication Number Publication Date
JP2022541550A JP2022541550A (ja) 2022-09-26
JP2022541550A5 true JP2022541550A5 (cg-RX-API-DMAC7.html) 2023-07-28

Family

ID=74193935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503463A Pending JP2022541550A (ja) 2019-07-19 2020-07-20 先天性副腎過形成を処置する方法

Country Status (11)

Country Link
US (2) US20220133742A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986416A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022541550A (cg-RX-API-DMAC7.html)
KR (1) KR20220052927A (cg-RX-API-DMAC7.html)
CN (1) CN114423436A (cg-RX-API-DMAC7.html)
AU (1) AU2020318970B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000956A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147891A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000812A (cg-RX-API-DMAC7.html)
TW (1) TW202116324A (cg-RX-API-DMAC7.html)
WO (1) WO2021016208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
JP2023537598A (ja) * 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ,インク. 多嚢胞性卵巣症候群を処置するための方法および組成物
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
MD20210019A2 (ro) 2021-04-12 2022-10-31 Максим МАСЮТИН Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
EP4402142A4 (en) * 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020910A2 (en) * 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN101516835A (zh) * 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
KR101088239B1 (ko) * 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Crf1 수용체 길항제로서의 티아졸 피라졸로피리미딘
JP2015516979A (ja) * 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト
KR20210064407A (ko) * 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
BR112020002967A2 (pt) * 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) * 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy

Similar Documents

Publication Publication Date Title
JP2025020148A5 (cg-RX-API-DMAC7.html)
IL286048B2 (en) Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation
Africander et al. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
Regidor et al. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone
Sitruk-Ware New progestogens: a review of their effects in perimenopausal and postmenopausal women
CA2326654A1 (en) Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
JP2019131587A (ja) 子宮内膜増殖を抑制するための組成物および方法
CN1075375C (zh) 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物
JP2007535922A5 (cg-RX-API-DMAC7.html)
JP2006527193A5 (cg-RX-API-DMAC7.html)
JP2011502172A5 (cg-RX-API-DMAC7.html)
JP2021512852A5 (cg-RX-API-DMAC7.html)
CN103298343A (zh) 类固醇和糖皮质激素受体拮抗剂组合疗法
Davtyan Four generations of progestins in oral contraceptives
CN110997667A (zh) 促肾上腺皮质激素释放因子受体拮抗剂
JP2008534533A5 (cg-RX-API-DMAC7.html)
Pluchino et al. One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu
JP2018062530A (ja) プロゲステロン依存性病態を処置する方法およびその組成物
IL312515A (en) Bispecific cd16a binders
Schane et al. ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1
WO2023163945A1 (en) Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
Zhu et al. Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
JP2005513024A5 (cg-RX-API-DMAC7.html)
Noori et al. Effects of estrogen and progesterone used in oral contraceptive pills: A review
IL312514A (en) Corticosteroid reduction in treatment with anti-cd38 antibodies